LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham [Yahoo! Finance]
LB Pharmaceuticals Inc (LBRX)
Company Research
Source: Yahoo! Finance
to approval in schizophrenia with a single Phase 3, the Phase 3 is underway with topline data expected in the second half of 2027 , and the February PIPE funds the company through the second quarter of 2029 , including NDA-enabling work and a 52-week safety extension. Drug design and positioning: LB-102 is a methylated derivative of amisulpride engineered for better brain penetration and once-daily low-dose dosing (50 mg roughly equivalent to 400 mg amisulpride by receptor occupancy) and is positioned to differentiate on cognition, anhedonia, and tolerability versus other antipsychotics. Clinical results: A 359-patient Phase 2 schizophrenia trial showed statistically significant PANSS improvements and dose-dependent cognitive benefits, with a favorable tolerability profile (low EPS, minimal prolactin and QT issues) supporting advancement to Phase 3. Interested in LB Pharmaceuticals Inc? Here are five stocks we like better. LB Pharmaceuticals (NASDAQ:LBRX) is seeking to build a
Show less
Read more
Impact Snapshot
Event Time:
LBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBRX alerts
High impacting LB Pharmaceuticals Inc news events
Weekly update
A roundup of the hottest topics
LBRX
News
- LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- LB Pharmaceuticals (LBRX) is now covered by Craig Hallum. They set a "buy" rating and a $36.00 price target on the stock.MarketBeat
- LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)GlobeNewswire
LBRX
Earnings
- 3/26/26 - In-Line
LBRX
Sec Filings
- 4/15/26 - Form EFFECT
- 4/14/26 - Form 424B3
- 4/6/26 - Form S-1
- LBRX's page on the SEC website